Pharma BD Deal Intelligence
Vaccines play failed: Novartis sold Chiron-derived unit to GSK after operating losses
Full analysis, sources & comparables →Novartis acquired Chiron Corporation for vaccines, blood testing, biopharmaceuticals.
Chiron shareholders approved Novartis' acquisition at $48.00 per share in cash, representing a total value of $5.4 billion and a 32% premium to the unaffected…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Novartis acquired Chiron Corporation for $48 per share ($5.4 billion) in an all-cash transaction, gaining a leading vaccines business, blood testing operations (with Gen-Probe), and a biopharmaceuticals pipeline. Novartis had held a 42% stake in Chiron since 1994.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Chiron Corporation (this deal) | 2002 | $5.4B | 53 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2002 deals · Novartis AG deals · Infectious Disease deals